All In Biotech

Drug Trial Radar · NCT04713514

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Aug 5, 2021

Primary completion

Dec 15, 2025

Study completion Nov 9, 2026

Sponsor

Lead sponsor
ARCAGY/ GINECO GROUPAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
OSE Immunotherapeutics; Merck Sharp & Dohme LLC
First posted
Jan 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study is an international randomized phase II, multicenter, open-label, three arms trial to assess best supportive care (BSC) vs OSE2101 and vs OSE2101 + pembrolizumab as maintenance treatment for patients with platinum sensitive relapsed ovarian cancers, previously treated with chemotherapy (regardless of the number of prior lines of platinum-based chemotherapy), bevacizumab (if eligible) and a PARP inhibitor (if eligible). Patients in Complete Response, Partial Response, or Stable Disease at the end of chemotherapy with at least 4 cycles of platinum based chemotherapy will be randomized in one of the three arms (randomization 1:1:2). They will receive one or the two study treatments or BSC until progression, or intolerance, or up to 2 years (from 1st study treatment dose).

Conditions

  • Platinum-sensitive Ovarian Cancer
  • Relapsed Ovarian Cancer

Interventions

  • OSE2101Drug

    subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

  • Pembrolizumab 25 MG/ML [Keytruda]Drug

    400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: from date to randomization to date of event, assessed up to 4 years

Locations

41 sites in 3 countries. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier de l'Ardenne Vivalia

    Libramont, Belgium

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

  • ICO Paul Papin

    Angers, France

  • Institut du Cancer Avignon-Provence

    Avignon, France

  • Centre Hospitalier de la Côte Basque

    Bayonne, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • Institut Bergonié

    Bordeaux, France

  • Centre François Baclesse

    Caen, France

  • Centre d'Oncologie et de Radiothérapie 37

    Chambray-lès-Tours, France

  • Centre Hospitalier de Cholet

    Cholet, France

  • Centre Jean PERRIN

    Clermont-Ferrand, France

  • Centre Georges François Leclerc

    Dijon, France

  • CHU Grenoble-Alpes - Site Nord (La Tronche)

    Grenoble, France

  • Centre Oscar Lambret

    Lille, France

  • CHU Limoges - Dupuytren

    Limoges, France

  • Hôpital Privé Jean Mermoz

    Lyon, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • ICM - Val d'Aurelle

    Montpellier, France

  • Hôpital Privé du Confluent

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Hôpital Pitié-Salpêtrière - AP-HP

    Paris, France

  • Hôpital Cochin

    Paris, France

  • Groupe Hospitalier Diaconesses-Croix Saint-Simon

    Paris, France

  • Center Hospitalier de Pau

    Pau, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre CARIO - HPCA

    Plérin, France

  • Centre Eugène Marquis

    Rennes, France

  • ICO - Centre René Gauducheau

    Saint-Herblain, France

  • CHU de Saint-Etienne - Pôle de Cancérologie

    Saint-Priest-en-Jarez, France

  • Centre Hospitalier Broussais

    St-Malo, France

  • CHU Strasbourg - Hôpital de Hautepierre

    Strasbourg, France

  • Institut Claudius Régaud

    Toulouse, France

  • Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Germany

  • Evang. Kliniken Essen-Mitte GmbH

    Essen, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Universitätsmedizin Mainz

    Mainz, Germany

  • Universitätsmedizin Mannheim GmbH

    Mannheim, Germany

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.